These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8151320)

  • 21. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
    Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
    J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
    Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
    Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive treatment of multiple myeloma and criteria for complete remission.
    Gore ME; Selby PJ; Viner C; Clark PI; Meldrum M; Millar B; Bell J; Maitland JA; Milan S; Judson IR
    Lancet; 1989 Oct; 2(8668):879-82. PubMed ID: 2571812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue.
    Powles R; Raje N; Cunningham D; Malpas J; Milan S; Horton C; Mehta J; Singhal S; Viner C; Treleaven J
    Stem Cells; 1995 Aug; 13 Suppl 2():114-7. PubMed ID: 8520498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma.
    Weaver CH; Zhen B; Schwartzberg LS; Leff R; Magee M; Geier L; Deaton K; Lewkow L; Buckner CD
    Bone Marrow Transplant; 1998 Aug; 22(3):245-51. PubMed ID: 9720737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma.
    Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Rigg A; Horton C; Singhal S; Mehta J; Treleaven J
    Br J Cancer; 2001 Aug; 85(3):325-32. PubMed ID: 11487259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-dose intravenous melphalan in advanced multiple myeloma.
    Bäck H; Lindblad R; Rödjer S; Westin J
    Acta Haematol; 1990; 83(4):183-6. PubMed ID: 2115714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
    Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
    Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous stem cell transplantation for multiple myeloma: identification of prognostic factors.
    Kumar L; Cyriac SL; Tejomurtula TV; Bahl A; Biswas B; Sahoo RK; Mukherjee A; Sharma O
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):32-41. PubMed ID: 23085487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
    Fenk R; Schneider P; Kropff M; Huenerlituerkoglu AN; Steidl U; Aul C; Hildebrandt B; Haas R; Heyll A; Kobbe G;
    Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma.
    Bishton M; Gilyead M; Das Gupta E; Williams C; Russell NH; Byrne JL
    Leuk Res; 2007 Aug; 31(8):1063-8. PubMed ID: 17324463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
    Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Nunzi M; Grasso M; Falco P; Cangialosi C; Boccadoro M
    Cancer; 2005 Oct; 104(7):1428-33. PubMed ID: 16116606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.